Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized in 90-95% of cases by the reciprocal t(9;22)(q34;q11) chromosomal translocation, that generates a BCR-ABL fusion gene on the derivative chromosome 22 [der(22)] or Philadelphia (Ph) chromosome. The BCR-ABL gene encodes a constitutively active tyrosine kinase, which leads to the activation of multiple signaling pathways involved in cell-cycle, adhesion and apoptosis. The aim of the chapter book was to bescribe risk statification models and prognostic factors, including baseline and response-related prognostic variables, with relevant impact on the outcome of CML patients.
Baccarani M., Castagnetti F., Iacobucci I., Palandri F., Pusiol A. (2007). Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables. OXFORD : Informa healthcare - Taylor & Francis publishers.
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables
BACCARANI, MICHELE;CASTAGNETTI, FAUSTO;IACOBUCCI, ILARIA;PALANDRI, FRANCESCA;
2007
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized in 90-95% of cases by the reciprocal t(9;22)(q34;q11) chromosomal translocation, that generates a BCR-ABL fusion gene on the derivative chromosome 22 [der(22)] or Philadelphia (Ph) chromosome. The BCR-ABL gene encodes a constitutively active tyrosine kinase, which leads to the activation of multiple signaling pathways involved in cell-cycle, adhesion and apoptosis. The aim of the chapter book was to bescribe risk statification models and prognostic factors, including baseline and response-related prognostic variables, with relevant impact on the outcome of CML patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
